| 000 | 01787 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516111451.0 | ||
| 264 | 0 | _c20130308 | |
| 008 | 201303s 0 0 eng d | ||
| 022 | _a1545-5017 | ||
| 024 | 7 |
_a10.1002/pbc.24281 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKim, AeRang | |
| 245 | 0 | 0 |
_aPhase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. _h[electronic resource] |
| 260 |
_bPediatric blood & cancer _cMar 2013 |
||
| 300 |
_a396-401 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 |
_aNeurofibroma, Plexiform _xdrug therapy |
| 650 | 0 | 4 |
_aNeurofibromatosis 1 _xcomplications |
| 650 | 0 | 4 |
_aNiacinamide _xadministration & dosage |
| 650 | 0 | 4 |
_aPhenylurea Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aSorafenib |
| 700 | 1 | _aDombi, Eva | |
| 700 | 1 | _aTepas, Kathleen | |
| 700 | 1 | _aFox, Elizabeth | |
| 700 | 1 | _aMartin, Staci | |
| 700 | 1 | _aWolters, Pamela | |
| 700 | 1 | _aBalis, Frank M | |
| 700 | 1 | _aJayaprakash, Nalini | |
| 700 | 1 | _aTurkbey, Baris | |
| 700 | 1 | _aMuradyan, Naira | |
| 700 | 1 | _aChoyke, Peter L | |
| 700 | 1 | _aReddy, Alyssa | |
| 700 | 1 | _aKorf, Bruce | |
| 700 | 1 | _aWidemann, Brigitte C | |
| 773 | 0 |
_tPediatric blood & cancer _gvol. 60 _gno. 3 _gp. 396-401 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/pbc.24281 _zAvailable from publisher's website |
| 999 |
_c22089548 _d22089548 |
||